Agenus (AGEN)
(Delayed Data from NSDQ)
$11.12 USD
+0.42 (3.93%)
Updated May 21, 2024 04:00 PM ET
After-Market: $11.11 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.12 USD
+0.42 (3.93%)
Updated May 21, 2024 04:00 PM ET
After-Market: $11.11 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Will Agenus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Agenus.
Are You Looking for a Top Momentum Pick? Why Agenus (AGEN) is a Great Choice
by Zacks Equity Research
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 13.16% and 27.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
by Zacks Equity Research
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
by Zacks Equity Research
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
by Zacks Equity Research
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Agenus (AGEN) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
by Zacks Equity Research
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Gilead & Galapagos Announce Positive Data on Arthritis Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
by Zacks Equity Research
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.